Asset Details
Do you wish to reserve the book?
The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis About Cohort Studies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis About Cohort Studies
Do you wish to request the book?
The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis About Cohort Studies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis About Cohort Studies
2024
Overview
Background and Aims There are still no useful biomarkers for the prognosis of esophageal squamous cell carcinoma (ESCC). In the prognosis of some kinds of cancer, soluble programmed death 1 (sPD‐1) and programmed death ligand 1 (sPD‐L1) have demonstrated statistical significance, but the prognostic value of serum sPD‐L1 and sPD‐1 remains unclear in ESCC. Methods Here, a meta‐analysis was performed to estimate the prognostic value of sPD‐L1 and sPD‐1 in ESCC. To obtain eligible studies, we searched mainstream databases (PubMed, Cochrane, Embase, Web of Science, Wanfang Data, and CNKI), and the survival data including hazard ratios (HR) and its 95% confidence intervals (95% CI) from included literature were extracted. Results Six articles were included, including 645 patients with ESCC. The statistical result of this meta‐analysis indicated that serum sPD‐1 had no significant correlation with overall survival (OS) of patients with ESCC (p > 0.05). Patients with ESCC with high concentrations of serum sPD‐L1 demonstrated a significantly poor prognosis (HR = 1.73, 95% CI: 1.42–2.11, p < 0.001). Conclusion Higher levels of serum sPD‐L1 may predict poor OS in ESCC patients, which may be a promising and credible prognostic biomarker for esophageal cancer.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
